chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID arm; Stuffy nose; drainage in throat; Plugged ears; right arm itching; right arm red; right arm hot; right arm hurt a little; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (right arm hurt a little), PRURITUS (right arm itching), ERYTHEMA (right arm red), SKIN WARM (right arm hot) and NASAL CONGESTION (Stuffy nose) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 dosage form. On 05-Feb-2021, the patient experienced PAIN IN EXTREMITY (right arm hurt a little). On 12-Feb-2021, the patient experienced PRURITUS (right arm itching), ERYTHEMA (right arm red) and SKIN WARM (right arm hot). On 02-Mar-2021, the patient experienced NASAL CONGESTION (Stuffy nose), OROPHARYNGEAL DISCOMFORT (drainage in throat) and EAR DISCOMFORT (Plugged ears). On an unknown date, the patient experienced VACCINATION SITE REACTION (COVID arm). On 19-Feb-2021, PRURITUS (right arm itching), ERYTHEMA (right arm red) and SKIN WARM (right arm hot) had resolved. At the time of the report, PAIN IN EXTREMITY (right arm hurt a little), NASAL CONGESTION (Stuffy nose), OROPHARYNGEAL DISCOMFORT (drainage in throat), EAR DISCOMFORT (Plugged ears) and VACCINATION SITE REACTION (COVID arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included Cortisone Cream..
Felt like I was going to die.  Have a loop recorder that recorded 286 beats per minute and in AFib
blood pressure higher than usual; pain at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD PRESSURE INCREASED (blood pressure higher than usual) and VACCINATION SITE PAIN (pain at the injection site) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036A21A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes and Blood pressure (Patient's blood pressure is higher than usual).    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, the patient experienced VACCINATION SITE PAIN (pain at the injection site). On 10-Mar-2021, the patient experienced BLOOD PRESSURE INCREASED (blood pressure higher than usual). At the time of the report, BLOOD PRESSURE INCREASED (blood pressure higher than usual) and VACCINATION SITE PAIN (pain at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications include blood pressure medication.  No treatment medication information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 04-May-2021: Follow up document was attached which contains NNI.
Patient said yes when asked if he had side effects but did not provide further information.; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Patient said yes when asked if he had side effects but did not provide further information.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Patient said yes when asked if he had side effects but did not provide further information.). At the time of the report, VACCINATION COMPLICATION (Patient said yes when asked if he had side effects but did not provide further information.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       no concomitant medications and treatment details reported.
IPV was given and Pediarix was accidentally given in place of DTaP, patient received 2 doses of IPV, contacted manufacturer and they stated no reason for concern, notified doctor of incident.
Two weeks post vax, the pt developed enlarging, tender, warm, erythematous wheal at site of injection.
sick; Initial information was received on 09-Oct-2020 regarding an unsolicited valid non-serious case from a consumer/non-health care professional via social media.  This case involves a patient (demographics not provided) who got sick (illness), after receiving INFLUENZA VACCINE.  Medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date: not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient got sick (illness) (unknown latency, non-serious) following the administration of INFLUENZA VACCINE.  No laboratory data was provided.  It was not reported if the patient received any corrective treatment.  At the time of report, the outcome of the event was unknown.  There will be no information available on batch number for this case.
pt recvd vax & 15 mins later devel sharp chest pain, lt arm was numb & tingly & poss panic attack sx; lasted 1 day;
Got vaccine 7:45 PM on 10/14/14 came back in with bruising around site and said it was sore.
Crying day & night x 5 days; crying stops when mom picks up and holds pt & resumes when put back down; No other sx of illness; Seen by MD 19AUG91; dx persistant AOM R>L, aphthous lesions on pharynx-viral etiol probable; rx augmentin;
Body aches; joint pain; Slight headache; This is a spontaneous report from a non-contactable consumer, the patient. A 62-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration on 30Mar2021 at 00:45 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19, hypothyroid, rheumatoid arthritis (RA) and depression. Concomitant medications were not reported. The patient previously received paracetamol; dextropropoxyphene hydrochloride (DARVOCET) and experienced drug allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021, the patient had body aches, joint pain and slight headache. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events body aches, joint pain, slight headache and included treatment with paracetamol (TYLENOL) and ibuprofen (ADVIL). The clinical outcomes of the events body aches, joint pain and slight headache were resolving at the time of the report.   No follow-up attempts are needed. No further information is expected.
gastrointestinal bleed; bacterial pneumonia; failure of his lungs and kidneys; failure of his lungs and kidneys; died; nursing center; fatigue; adverse event; This spontaneous report was received from a consumer (a patient's wife) and refers to a male patient of unknown age. No information regarding the patient's medical history, concomitant medications and concurrent conditions was provided.   On an unspecified date in 2000, the patient was vaccinated with the first dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23)(strength, frequency, route of administration, lot# and expiration dates were not provided) for prophylaxis. On an unknown date in 2017, he received second dose (lot # and expiry date were not provided).  On an unspecified date in 2017, the patient experienced adverse event. On an unspecified date, the patient experienced gastrointestinal bleeding and was hospitalized, he received two units of packed red blood cells. During this stay, in 2019, the patient received his third dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23)(lot # and expiry date were not provided) and unspecified "flu shot". On an unspecified date in 2019, after about three weeks after being discharged from the hospital, the patient started experiencing fatigue. The patient sought medical attention and was admitted to the hospital for a second time, where he was diagnosed with bacterial pneumonia. The patient was given unspecified antibiotics and experienced failure of his lungs and kidneys (approximately in 2019, exact date was not provided). On an unspecified date in 2019, the patient died, after being transferred to nursing center. Cause of death was not reported. It was unknown if an autopsy was performed. The outcome of pneumonia bacterial, fatigue, gastrointestinal haemorrhage, renal failure and respiratory failure was reported as not recovered/not resolved. The outcome of adverse event was unknown. The causality assessment between pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) and the events was not provided.  Upon internal review, the events of renal failure, respiratory failure, pneumonia bacterial and gastrointestinal haemorrhage were determined to be medically significant.
Patient received a sub-optimal COVID-19 vaccine due to a storage and handling error. Vaccine was stored in a regular freezer prior to being refrigerated and then administered. Requested that a VAERS form be submitted for this patient.
Information has been received from a nurse concerning a patient of unknown age and gender. The patient's information about concurrent condition, medical history, drug reactions/allergies and concomitant therapy was not provided. On 08-NOV-2016, the patient  inadvertently received an expired dose of M-M-R II (expiration date: on an unspecified date in August 2016) (lot# and dose were not reported) subcutaneously. No adverse effects reported. Additional information has been requested.
Initial unsolicited report received from a consumer via social media on 10-Oct-2016. This case is linked with 2016SA188144, 2016SA188556, 2016SA188803, 2016SA188804, 2016SA188805, 2016SA188806, 2016SA188807, 2016SA188808, 2016SA188809, 2016SA188810, 2016SA188811, 2016SA188812, 2016SA188813, 2016SA188814, 2016SA188815, 2016SA188816, 2016SA188817, 2016SA188818, 2016SA188819, 2016SA188820, 2016SA188821, 2016SA188822, 2016SA188833, 2016SA188834, 2016SA188835, 2016SA188837, 2016SA188838, 2016SA188839, 2016SA188840, 2016SA188841, 2016SA188842, 2016SA188843, 2016SA188844, 2016SA188845, 2016SA188846, 2016SA188847, 2016SA188848, 2016SA188849, 2016SA188850, 2016SA188851 (Same reporter source, same vaccine). This case involves a patient (age and gender not reported) who was vaccinated with a dose of Flu shot (manufacturer: unknown, batch number, expiry date, dose, dose in series, route and site of administration were not reported) on unspecified date. The patient's medical history and concomitant medications were not reported. On an unspecified date, following the vaccination, patient got sick and almost died. The patient's laboratory data and corrective treatment was not reported. The outcome of events were not reported. Case was considered as serious due to life threatening events: almost died and sick. List of documents held by sender: none. Sender's Comments: This poorly document case as patient got sick and almost after flu shot, detail medical history, any comorbidity, past vaccination history and its tolerance are needed to further assess the case.
8 hrs p/vax mom called saying pt crying for last 3 hrs & legs is swollen, hot & red up to the knee;
Patient is fully vaccinate and booted on 10/2/2021.  COVID + on 12/10/2021. ED visit on 12/10/2021.  75-year-old female past medical history of symptomatic anemia and GI bleed presenting with chief complaint of nausea, diarrhea, fatigue. She describes a watery diarrhea over the last 4 days. She began feeling nauseous this morning prompting her visit. She says that overall she is feeling more fatigued than normal. She denies shortness of breath or pallor. Denies any abdominal pain. Denies chest pain or shortness of breath. Patient does admit to a new onset cough that started yesterday evening. She describes it is dry and hacking. Denies fever or chills. BP 133/83  | Pulse 109  | Temp 99.1 °F (37.3 °C) (Oral)  | Resp 17  | Ht 172.7 cm (5' 8")  | Wt 64.4 kg (142 lb)  | SpO2 95%  | BMI 21.59 kg/m² She was given follow-up instructions for monoclonal antibody therapy and sent home with a prescription for Bactrim for UTI.
This spontaneous report as received from a consumer refers to a 73 years old female patient. The patient was vaccinated with PNEUMOVAX23 on 05-DEC-2012 (Lot # unspecified). No other co-suspects were reported. No concomitant medications were reported. By 11.00 pm on 05-DEC-2012 the patient experienced 102F fever and chills, arm was red, hard and painful from her shoulders to her elbow. The patient contacted the pharmacy on 26-DEC-2012 for medical recommendation. Two BENADRYL tablets were taken for treatment. The outcome of fever and chills was reported as recovered/resolved by the morning of 06-DEC-2012. The outcome of arm was red and painful was reported as not recovered/not resolved. The relatedness for fever and chills and arm was painful and red is unknown for PNEUMOVAX23. Additional information has been requested.
Tongue swelled 15 minutes after first dose of vaccine.; This spontaneous case was reported by a consumer and describes the occurrence of SWOLLEN TONGUE (Tongue swelled 15 minutes after first dose of vaccine.) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003B21A) for COVID-19 vaccination.     Patient was never tested positive for COVID. No Acute and chronic illnesses at the time of vaccination. No other vaccines given within 1 month prior to Moderna COVID-19 vaccine.  Concurrent medical conditions included Egg allergy (since she was a child).    On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Mar-2021, the patient experienced SWOLLEN TONGUE (Tongue swelled 15 minutes after first dose of vaccine.). On 24-Mar-2021, SWOLLEN TONGUE (Tongue swelled 15 minutes after first dose of vaccine.) had resolved.    mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged. No concomitant medications were reported. Did adverse event cause patient to seek medical care: No.  Event outcome reported as recovered after few minutes. No treatment medications were reported.   This case was linked to MOD-2022-547115 (Patient Link).
20-30 vesicular lesions in total which lasted only several days.  Patient only should by all.
Initial flu vaccine given 1-6-2009.  Had fever for 48 hours and fussiness after that vaccine.  Had 2nd dose of flu vaccine 2-9-2009.  Within an hour or two developed vomiting, diarrhea and fever which persists through today.  In addition to vaccines below had flu shot 2-9-2009, sanofi, lot U2764AA in left thigh
Pt at well child exam, had Hemoglobin finger stick test done followed by HEPATITIS A vaccination. Pt became pale, experienced syncope, but did not lose consciousness, was placed in supine position given juice to drink - then recovered.
Two days after the second dose I had a dark red image appear on my right arm where veins are located. Went away within one day. On 7/14, another dark red image appeared on my left leg below the knee. These spots were not present before the second shot. I have taken a picture of the one on my knee to show my doctor next week at the appt. Appt scheduled for 7/19
Full body rash for 2.5 days and weakness for about 5 days. Resolved without medical intervention.
.  On Friday: 1/22/2021: started having itching starting at the ankles, circumfrentially, symmetrical on both legs.  This continued upward the legs to the body.  Back and back of arms.
Very enlarged lymph nodes under thearm where the vaccine wasadministered; tenderness, and swollenlymph nodes.; Swollen lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 01Apr2021 at 12:30 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 18:00, the patient had very enlarged lymph nodes under the arm where the vaccine was administered, tenderness and swollen lymph nodes. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events enlarged lymph nodes under the arm, tenderness, and swollen lymph nodes which included treatment with Tylenol and hot compresses. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events enlarged lymph nodes under the arm, tenderness and swollen lymph node in left underarm was resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
approx 10min p/vax pt listless, lethargic, hypoconscious, pale, but no resp distress pt assessed & VS started stat w/in 30min pt alert w/no sx;
Two events of chest pain and discomfort. One event on April 5th that lasted that full day and another event on April 13th that lasted until about April 21st. I had a CT Scan,  EKG, and X-ray and nothing was identified. I began taking aspirin daily beginning on the 14th until the 21st. I am currently not experiencing any chest pain or discomfort.
Information has been received from a physician concerning a female who on 12-DEC-2007 was vaccinated with a first dose of Zostavax (Oka/Merck) (Lot # 658398/1087U).  Five weeks post vaccination, in approximately February 2007, the patient developed skin eruptions, with clusters along 6-7 rib line.  At the time of reporting the patient was still being treated.  No further information provided.  Additional information has been requested. 02/17/2010 Information has been received from a physician concerning a 74 year  old female with osteoporosis and hypertension at the time of vaccination and no known drug allergies who on 12-DEC-2007 was vaccinated into the left deltoid with a first dose of ZOSTAVAX (Lot # 658398/1087U). Five weeks post vaccination in approximately February 2007, the patient developed skin eruptions, with clusters along 6-7 rib line. At the time of reporting the patient was still being treated, and the final outcome was unknown. There was no lab diagnostic studies performed. No further information was provided. Additional information has been been requested.
1st dose 2018, 2nd not yet; This case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in 2018).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date: 01-DEC-2022 Reporter's comment: The reporter stated that the patient received first dose of Shingrix in 2018 and has not yet received her second dose. Additional supportive information: Till the time of reporting the patient did not receive the second dose of Shingrix which led to incomplete course of vaccination. Reporter did not consented to follow up.
Patient has 6 cm diameter area, firm induration increased warmth with erythema and increased warmth on right deltoid.
Pt called clinic from home and reported chest pain, metallic taste, tingling sensation around mouth, shortness of breath. Pt advised to call 911 and seek medical attention at an emergency room.
a little ill; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (a little ill) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (a little ill). At the time of the report, ILLNESS (a little ill) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. No treatment information was reported.
Shortly after receiving vaccine patient reported that she felt like her throat was really dry and she was hoarse. Did not feel like she had swelling or trouble breathing but reported a history of anaphylaxis to contrast dye. Patient was given Benadryl 50mg IM in rt deltoid and observed for another hour. Sent home with EpiPen and instructed to take Benadryl 25mg every 6 hours x 24 hours. ER precautions given.
A report has been received from a physician concerning a patient, male subject, who had been receiving FLUMIST QUADRIVALENT (intranasal). FLUMIST QUADRIVALENT (intranasal) started on an unknown date. It was reported that the patient was administered expired FLUMIST QUADRIVALENT on 08-Sep-2014. The outcome of the event of administered expired FLUMIST QUADRIVALENT is unknown. The report was considered to be non-serious.
Knocked out for on day and a half; Headache; chills; Exhausted; This spontaneous case was reported by a consumer and describes the occurrence of LOSS OF CONSCIOUSNESS (Knocked out for on day and a half) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 046A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Osteoporosis.   On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced LOSS OF CONSCIOUSNESS (Knocked out for on day and a half) (seriousness criterion medically significant), HEADACHE (Headache), CHILLS (chills) and FATIGUE (Exhausted). At the time of the report, LOSS OF CONSCIOUSNESS (Knocked out for on day and a half), HEADACHE (Headache), CHILLS (chills) and FATIGUE (Exhausted) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medication were reported The treatment for the events was not provided   This case was linked to MOD-2021-067568 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Information has been received from a pharmacist referring to a 65 year old male patient. The patient developed herpes in his eyes over a year ago. On 15-SEP-2016 the patient was vaccinated with one dose of ZOSTAVAX (lot # M024700, expiration date 18-JUL-2016, dose was unknown, subcutaneous). Other suspect therapies included acyclovir (dose and frequency were unknown) for herpes in his eyes. No PQC was involved. The outcome of the event was unknown. The causality between the event and suspect therapies was not reported. Additional information has been requested.